Citius Oncology, Inc. Common Stock
CTORCitius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on developing targeted cancer therapies. The company aims to advance innovative treatments by leveraging immunology and oncology research to improve outcomes for cancer patients.
Company News
Citius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.
Citius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Citius Oncology closed a $9.0 million registered direct offering and private placement, issuing 5,142,858 shares of common stock and accompanying warrants at $1.75 per share, with warrants exercisable at $1.84 per share.
Citius Oncology has entered a securities purchase agreement to sell 5,142,858 shares of common stock at $1.75 per share, with concurrent warrants, expected to raise approximately $9.0 million.
Citius Oncology reported its Q3 2025 financial results, highlighting preparations for the commercial launch of LYMPHIR, a therapy for cutaneous T-cell lymphoma, with $12.5 million raised to support pre-launch initiatives.
